Tag Archives: Alzheimer’s Disease Assessment Scale (ADAS-Cog11)

National Screening for Dementia Not Recommended (UK NSC / AHRQ / Annals of Internal Medicine / Epidemiology / International Journal of Epidemiology)

Summary The UK National Screening Committee (UK NSC) has upheld previous recommendations against screening people aged 65 and over for dementia. This decision follows an extensive review of the evidence. The UK NSC has concluded that tests for dementia, which … Continue reading

Posted in Acute Hospitals, Community Care, Department of Health, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Guidelines, Models of Dementia Care, National, NHS, Patient Care Pathway, Person-Centred Care, Practical Advice, Public Health England, Quick Insights, Standards, UK, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Metal Protein Attenuating Compounds for Alzheimer’s Disease (Cochrane Database)

Summary This systematic review evaluates the efficacy of metal protein attenuating compounds (MPACs) for the treatment of cognitive impairment in Alzheimer’s dementia. Earlier experimentation and mouse model studies had indicated that MPACs might promote the dissolution and clearance of beta-amyloid … Continue reading

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Pharmacological Treatments, Systematic Reviews, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Bapineuzumab Trials Results in Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Summary Bapineuzumab is an anti-amyloid-beta monoclonal antibody, which had shown promise for the treatment of Alzheimer’s Disease. Two double-blind, randomised, placebo-controlled, phase 3 trials have been conducted, involving 2204 patients with mild-to-moderate Alzheimer’s disease. One trial involved 1121 carriers of … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Solanezumab Trials Results for Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Summary Solanezumab is a monoclonal antibody which binds soluble amyloid preferentially and had shown some promise of promoting better clearance of amyloid-beta from the brain in pre-clinical studies. Two placebo controlled trials (EXPEDITION 1 and EXPEDITION 2) of 1012 and … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment